search
Back to results

Maternal Depression Treatment in HIV (M-DEPTH)

Primary Purpose

Depression

Status
Active
Phase
Phase 2
Locations
Uganda
Study Type
Interventional
Intervention
evidence-based depression treatment
Sponsored by
RAND
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Depression

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  • detection of pregnancy through 24 weeks gestation (to ensure at least 12 weeks remaining antenatal period for assessing adherence to all stages of PMTCT care cascade)
  • HIV-positive
  • positive screen for potential depression on 2-item Patient Health Questionnaire (PHQ-2>0)
  • on ART for at least 4 weeks

Exclusion Criteria:

  • unstable health (about to start ART or on ART < 4 weeks; active, untreated opportunistic infection)

Sites / Locations

  • Makerere University

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

Depression Care

Usual care

Arm Description

Task-shifted depression care, consisting of (1) depression screening and psychoeducation, (2) depression diagnosis, and (3) evidence-based problem solving therapy (PST) or antidepressant therapy (ADT; for those with severe and refractory depression, or who decline PST), to be implemented by trained peer mothers and midwife nurses in addition to usual care.

Usual care processes for treating depression consist of referrals to mental health specialists and access to the Family Support Group program (a nation wide Ministry of Health program for HIV+ women at public ANC clinics, consisting of monthly sessions designed to provide psychosocial support and education to promote pregnancy management and PMTCT adherence).

Outcomes

Primary Outcome Measures

Rate of maternal HIV viral suppression
Proportion of participants who achieve undetectable HIV viral load as measured by blood assay
Mean maternal antiretroviral (ART) adherence
Group mean proportion of prescribed ART doses taken as measured by pharmacy refill data
Rate of prevention of mother-to-child-transmission (PMTCT) care retention
Proportion of participants who continue to attend antenatal care (ANC) visits as measured by chart abstraction
Rate of delivery in health facility
Proportion of participants who delivery their baby of in a health facility as measured by chart abstraction
Rate of infant use of ART
Proportion of delivered infants who receive ART as measured by chart abstraction
Rate of universal infant feeding
Proportion of delivered infants who receive uniform feeding method (breastfeeding or formula) as documented by self-report
Rate of complete infant HIV testing
Proportion of delivered infants who are tested for HIV at all specified intervals, as measured by chart abstraction

Secondary Outcome Measures

Child HIV status
HIV status of child

Full Information

First Posted
March 21, 2019
Last Updated
July 20, 2023
Sponsor
RAND
Collaborators
Makerere University, Mildmay Uganda Limited
search

1. Study Identification

Unique Protocol Identification Number
NCT03892915
Brief Title
Maternal Depression Treatment in HIV
Acronym
M-DEPTH
Official Title
Depression Care to Improve Adherence to Prevention of Mother-to-Child-Transmission (PMTCT) Care Continuum & Pregnancy Outcomes
Study Type
Interventional

2. Study Status

Record Verification Date
July 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
July 8, 2019 (Actual)
Primary Completion Date
August 31, 2023 (Anticipated)
Study Completion Date
May 31, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
RAND
Collaborators
Makerere University, Mildmay Uganda Limited

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Cluster randomized controlled trial to compare the effects of task-shifted, evidence-based depression care vs. usual care on adherence to each step of the prevention of mother-to-child-transmission (PMTCT) care cascade at 8 antenatal care (ANC) clinics in Uganda.
Detailed Description
This study is a cluster randomized controlled trial (RCT) to compare the effects of task-shifted, evidence-based depression care vs. usual care on adherence to each step of the PMTCT care cascade at 8 ANC clinics in Uganda. At 4 experimental sites, task-shifted, depression care will include (1) depression screening and psychoeducation, (2) depression diagnosis, and (3) provision of evidence-based problem solving therapy (PST), or antidepressant therapy (ADT) for those with severe and refractory depression (or who decline PST), to be implemented by trained peer mothers and midwife nurses, respectively. The 4 control sites will use usual care services for managing depression, which consist of referrals to a mental health specialist and access to the Family Support Group program (comprehensive, monthly multi-session psychosocial program to enhance pregnancy management and PMTCT adherence). At each site, 50 HIV-positive newly pregnant women (total n=400) who screen positive for potential depression will be enrolled and followed until 18-months post-delivery to assess how depression and depression alleviation relate to primary (adherence to each component of the PMTCT care continuum, maternal virologic suppression) and secondary (infant HIV status; post-natal maternal and child health outcomes) outcomes, as well as processes of depression care (treatment uptake and depression alleviation among clinically depressed patients). A cost-effectiveness analysis will be used to compare the two study arms.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Depression

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2, Phase 3
Interventional Study Model
Parallel Assignment
Model Description
Cluster randomized controlled trial with 4 sites randomly assigned to implement evidence-based depression care in addition to usual care and 4 sites randomly assigned to implement usual care only
Masking
None (Open Label)
Allocation
Randomized
Enrollment
391 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Depression Care
Arm Type
Experimental
Arm Description
Task-shifted depression care, consisting of (1) depression screening and psychoeducation, (2) depression diagnosis, and (3) evidence-based problem solving therapy (PST) or antidepressant therapy (ADT; for those with severe and refractory depression, or who decline PST), to be implemented by trained peer mothers and midwife nurses in addition to usual care.
Arm Title
Usual care
Arm Type
No Intervention
Arm Description
Usual care processes for treating depression consist of referrals to mental health specialists and access to the Family Support Group program (a nation wide Ministry of Health program for HIV+ women at public ANC clinics, consisting of monthly sessions designed to provide psychosocial support and education to promote pregnancy management and PMTCT adherence).
Intervention Type
Combination Product
Intervention Name(s)
evidence-based depression treatment
Intervention Description
We will use a stepped care approach to depression treatment. Participants with clinical depression (defined as PHQ-9>9) will be offered either Problem Solving Therapy (PST) or Antidepressant Therapy (ADT), but those with moderate to moderately severe depression will be recommended PST, while those with severe depression will be recommended ADT. Participants with subthreshold depressive symptoms (PHQ-9: 5-9) will receive depression psychoeducation and continued depressive monitoring.
Primary Outcome Measure Information:
Title
Rate of maternal HIV viral suppression
Description
Proportion of participants who achieve undetectable HIV viral load as measured by blood assay
Time Frame
One month post pregnancy
Title
Mean maternal antiretroviral (ART) adherence
Description
Group mean proportion of prescribed ART doses taken as measured by pharmacy refill data
Time Frame
From study enrollment to one-month post pregnancy
Title
Rate of prevention of mother-to-child-transmission (PMTCT) care retention
Description
Proportion of participants who continue to attend antenatal care (ANC) visits as measured by chart abstraction
Time Frame
through study completion, an average of 48 weeks
Title
Rate of delivery in health facility
Description
Proportion of participants who delivery their baby of in a health facility as measured by chart abstraction
Time Frame
one month post pregnancy
Title
Rate of infant use of ART
Description
Proportion of delivered infants who receive ART as measured by chart abstraction
Time Frame
First 6 weeks of life
Title
Rate of universal infant feeding
Description
Proportion of delivered infants who receive uniform feeding method (breastfeeding or formula) as documented by self-report
Time Frame
First 6 months of life
Title
Rate of complete infant HIV testing
Description
Proportion of delivered infants who are tested for HIV at all specified intervals, as measured by chart abstraction
Time Frame
18 months after birth
Secondary Outcome Measure Information:
Title
Child HIV status
Description
HIV status of child
Time Frame
18 months after birth

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: detection of pregnancy through 24 weeks gestation (to ensure at least 12 weeks remaining antenatal period for assessing adherence to all stages of PMTCT care cascade) HIV-positive positive screen for potential depression on 2-item Patient Health Questionnaire (PHQ-2>0) on ART for at least 4 weeks Exclusion Criteria: unstable health (about to start ART or on ART < 4 weeks; active, untreated opportunistic infection)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Glenn Wagner, PhD
Organizational Affiliation
RAND
Official's Role
Principal Investigator
Facility Information:
Facility Name
Makerere University
City
Kampala
Country
Uganda

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
We will make the data publicly available in the form of an electronic database for researchers who successfully complete a registration process. Data will be de-identified. We will provide documentation in the form of a codebook in which each variable name and response options are defined. Users must agree to the conditions of use governing access to the public release data. Users must submit brief proposals regarding intended use of the data; the study team will determine the scientific soundness of the proposal, as well as whether adequate data protections in place, as part of the decision for the researcher to be able to access the public use dataset.
IPD Sharing Time Frame
Following publication of the main paper(s) for this study and the grant end-date.
IPD Sharing Access Criteria
Users must submit brief proposals regarding intended use of the data; the study team will determine the scientific soundness of the proposal, as well as whether adequate data protections in place, as part of the decision for the researcher to be able to access the public use dataset.
Citations:
PubMed Identifier
36127627
Citation
Wagner GJ, Gwokyalya V, Akena D, Nakigudde J, McBain R, Faherty L, Ngo V, Nakku J, Kyohangirwe L, Banegura A, Beyeza-Kashesya J, Wanyenze RK. Stressors and Maladaptive Coping Mechanisms Associated with Elevated Perinatal Depressive Symptoms and Suicidality Among Women Living with HIV in Uganda. Int J Behav Med. 2023 Oct;30(5):743-752. doi: 10.1007/s12529-022-10124-3. Epub 2022 Sep 20.
Results Reference
derived
PubMed Identifier
31277180
Citation
Wagner GJ, McBain RK, Akena D, Ngo V, Nakigudde J, Nakku J, Chemusto H, Beyeza-Kashesya J, Gwokyalya V, Faherty LJ, Kyohangirwe L, Nabitaka LK, Lukwata H, Linnemayr S, Ghosh-Dastidar B, Businge J, Mukasa B, Wanyenze RK. Maternal depression treatment in HIV (M-DEPTH): Study protocol for a cluster randomized controlled trial. Medicine (Baltimore). 2019 Jul;98(27):e16329. doi: 10.1097/MD.0000000000016329.
Results Reference
derived

Learn more about this trial

Maternal Depression Treatment in HIV

We'll reach out to this number within 24 hrs